Benzinga | Mar 9, 2021 09:16AM EST

Credit Suisse Initiates Coverage On Clover Health Investments with Neutral Rating, Announces Price Target of $10

Credit Suisse analyst Jailendra Singh initiates coverage on Clover Health Investments (NASDAQ:CLOV) with a Neutral rating and announces Price Target of $10.